Secretory Carcinoma of Male Breast: Case Report and Review of the Literature by Gabal, S. & Talaat, S.
SAGE-HindawiAccess to Research
International Journal of Breast Cancer
Volume 2011, Article ID 704657, 5 pages
doi:10.4061/2011/704657
Case Report
Secretory CarcinomaofMale Breast:
CaseReport andReview oftheLiterature
S.GabalandS.Talaat
Department of Pathology, Faculty of Medicine, Cairo University, Giza 12655, Egypt
Correspondence should be addressed to S. Gabal, ns gabal@yahoo.com
Received 1 October 2010; Accepted 9 January 2011
Academic Editor: Owen A. Ung
Copyright © 2011 S. Gabal and S. Talaat. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Secretory carcinoma is a rare low-grade breast carcinoma, initially termed “juvenile breast cancer,” but it is now known to occur
in adults of both sexes. It is the only epithelial tumor of the breast with a balanced translocation, t(12;15), that creates an ETV6-
NTRK3 gene translocation. In this paper, a 19-year-old male patient has had a right breast mass for 9 years which suddenly
increased in size with no evidence of palpable axillary lymph nodes. The mass was excised for frozen section and was diagnosed
as malignant growth for simple mastectomy. Microscopic examination revealed the classical features of secretory carcinoma. The
tumor cells were positive for EMA and S-100 protein and focally positive for cytokeratin and ER but negative for progesterone
receptor, CD34, and CEA. Four months later the patient developed ipsilateral axillary lymph node enlargement, with lymph node
metastases in ﬁve of the dissected 19 lymph nodes. The patient was treated with six courses of chemotherapy and radiotherapy.
Conclusion. Though considered an indolent neoplasm, secretory carcinoma does metastasize to lymph nodes. Surgery in the form
of mastectomy with axillary clearance is the treatment of choice. This paper includes a rare case report of secretory carcinoma in
young male patient, with axillary lymph node metastasis in spite of the indolent nature that this tumor is known to display.
1.Background
Secretory carcinoma is a rare (<1%) low-grade breast
carcinoma. it is most common under the age of 30, and it
is the most common type of breast carcinoma in children
[1]. This entity was initially termed “Juvenile breast cancer”
by McDivitt and Stewart, based on the fact that the average
age of the seven patients described in their series was nine
years old with a range of three to ﬁfteen years [2]. Although
originally described in children, it is now known to occur
in adults of both sexes [3], and male to female ratio is 1:6
[4]. The tumor is the only epithelial tumor of the breast
withabalancedtranslocation,t(12;15),thatcreatesanETV6-
NTRK3 gene translocation [3]. The biological consequence
ofthistranslocation isthefusion ofthe dimerization domain
of a transcriptional regulator (ETV6) with a membrane
receptor tyrosine kinase (NTRK3) that activates the Ras-
Mek1andPI3K-Aktpathwayswhich areimportant forbreast
cell proliferation and survival. This speciﬁc translocation
is associated with congenital ﬁbrosarcoma and mesoblastic
nephroma, two morphologically similar pediatric mesenchy-
mal tumors with no epithelial features [7].
The diagnostic microscopic criteria are abundant gran-
ular cytoplasm or clear vacuolated cytoplasm. Tubule for-
mation is common and may have secretion in the lumens.
Follicularpattern(thyroid-like) might be seen. The secretory
material in cells, lumens, and stroma is mucicarmine, alcian
blue, and PAS positive, diastase resistant. Fibrous bands are
often prominent. It is characterized by low-grade nuclear
cytology, bland, uniform nuclei, and rare mitotic ﬁgures.
Sheet-like growth with mainly circumscribed margins with
occasional foci of inﬁltration and in situ component are
common [1].
Very few authors have performed immunohistochemical
studies on secretory carcinomas of male breasts. These
tumors are said to be epithelial membrane antigen, cytok-
eratin, carcinoembryonic antigen (polyclonal), S-100, and α
lactalbumin positive [8].
Though considered an indolent neoplasm, secretory
carcinoma does metastasize to lymph nodes and recur after2 International Journal of Breast Cancer
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Figure 1: Secretory carcinoma shows microcystic pattern and intraluminal secretion, (a) (H&E) and (b) (PAS).
local excision [9]. Tavassoli and Norris suggested three
features of secretory carcinoma that indicate a favorable
prognosis: tumor size less than 2cm, age of less than 20 years
atdiagnosis,andtumorwithcircumscribedmargins [10].De
Bree found that secretory carcinomas in men appear to be
more aggressive [11].
Surgery in the form of mastectomy with axillary clear-
ance is the treatment of choice [9].There are severalreported
cases ofpatients with secretory breastcarcinoma with distant
metastases who were treated with either single agent or
combination chemotherapy without success. Among the
drugs reported are 5-FU, vindesine, mitomycin, prednisone,
adriamycin, epirubicin, cyclophosphamide, carboplatin, and
even newer active agents such as docetaxel. These data
clearly show that this neoplasm is not chemosensitive as all
of the patients treated with chemotherapy showed disease
progression while on treatment [4].
2.CaseReport
A 19-year-old male patient has had a right breast mass
for 9 years which suddenly increased in size with no
evidence of palpable axillary lymph nodes. Serum tumor
markers and other routine blood test were normal. The liver
ultrasonography, chest X-ray, and bone scan were negative
for metastases. The mass was excised for frozen section and
was diagnosed as malignant growth for simple mastectomy.
Grossly, the mass was circumscribed, 2 × 2cm, ﬁrm, and
had white glistening cut section. Microscopic examination
revealed the classical features of secretory carcinoma with a
microcystic pattern (Figure 1(a)) with abundant intra and
extracellular PAS-positive secretory material (Figure 1(b)).
The tumor cells were mostly bland looking with round
or oval nuclei and had few scattered nucleoli. No tumor
inﬁltration was present at the nipple or at surgical margins.
On immunohistochemistry, the tumor cells were positive for
EMA and S-100 protein and focally positive for cytokeratine
and ER (Figures 2(a), 2(b), 2(c),a n d2(d))b u tn e g a t i v ef o r
progesterone receptor, CD34, and CEA (Dako, Carpinteria,
CA, USA).
Four months later the patient developed ipsilateral axil-
lary lymph nodesenlargementwhich when biopsiedrevealed
lymph node metastasis of the previously excised secretory
carcinoma. Then the patient underwent axillary evacuation.
On microscopic examination, lymph node metastases were
detected in ﬁve of the dissected 19 lymph nodes. Then it
was decided for the patient to be treated with six courses of
chemotherapy and radiotherapy.
3.Discussion
Secretory carcinoma is a very rare type of breast carcinoma.
Tavassoli and Norris [10]r e p o r t e d4c a s e so fS Ci na
retrospective series of 7038 breast carcinoma cases, and De
Bree et al. [11] found one case of SC among 3000 breast
carcinoma cases.
The age at presentation varies from 3 to 66 years with
am e d i a na g eo f2 3y e a r s[ 8] .T h ec a s ep r e s e n t e dh e r e i n
is extremely unusual as secretory carcinoma, particularly
metastatic secretory carcinoma, has rarely been reported in
males. Literature search identiﬁed only 18 other cases in
males. Our case was older than the average age reported for
secretory carcinoma in males which is 17 years. Only the
case reported by Kuwabara was in old age (66 years) [9].
Table 1 summarizes the main clinical features of the cases of
secretory carcinoma reported in males.
Secretory carcinomas can demonstrate several histolog-
ical patterns including, solid, microcystic, and ductal, with
many tumors containing all three patterns [25]. The tumor
cells are polygonal with granular eosinophilic cytoplasm,
with intracellular and extracellular PAS- and alcian-blue-
positive secretions [25]. Atypia is minimal or absent and
mitotic activity is low [26]. A study has reported that only
4 and 2 out of 13 cases expressed estrogen and progesterone
receptor, respectively, and only two were HER2 positive [27].
In the current case, the tumor had positive ER and negative
progesterone receptors.
The most frequent clinical presentation is of an asymp-
tomatic mobile mass, which is usually subareolar. The tumor
size varies from 1cm to 16cm with an average diameter ofInternational Journal of Breast Cancer 3
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Figure 2: The tumor cells show positive nuclear and cytoplasmic staining by S100 antibody (a) positive cytoplasmic staining by EMA
antibody, (b) positive cytoplasmic staining by pan cytokeratin, (c) and some showed positive nuclear stainingby ER antibody (d).
3cm[28]. Our patient had a mass of2 × 2cm.Asthepatient
reported that the lesion had been present for at least 9 years,
it is assumed that it had behaved in a slow growing, indolent
fashion. This is supported by other reported cases [25]. In
this regard, Herz et al. have reported a MIB1 labeling index
of 11.4% (range: <1 to 34%) [26].
Surgery is considered the primary treatment of secretory
carcinoma; however, due to scarcity of reported cases, no
published guidelines for surgical management exist. How-
ever, few studies reported local recurrence in some patients
therefore, mastectomy appears to be a sound surgical choice
[1, 11, 25, 29]. There are no data, however, on conservative
treatment, but this option could be explored particularly
in cases where breast development has not yet occurred.
In regard to the management of the axilla, the overall
incidence of axillary lymph node inﬁltration is around 30%
in children and adults regardless of gender [28]; hence,
axillary lymph node dissection is advocated by some authors
for tumors ≥2cm[25]. Nevertheless, sentinel node biopsy,
may be useful for secretory carcinomas. A recent report on
a 9-year-old girl treated with simple mastectomy and axillary
sentinel lymph node biopsy shows that this is feasible [29].
Postoperative radiotherapy [28] and adjuvant chemo-
therapy [10] have been used on at least two occasions.
There is at present insuﬃcient evidencetorecommend either
approach in the management of secretory carcinoma.
Local recurrence after a long disease-free interval has
been described in numerous cases; [1, 8, 12, 30], how-
ever these occurred in patients that underwent conserva-
tive surgery. Distant metastases from secretory carcinoma
are extremely rare with only four cases reported [4].
Another reported patient remained disease free at a follow-
up of 13 months despite having 12 out of 14 positive
nodes and not having received adjuvant chemotherapy
[11].
4.Conclusion
Secretory carcinoma is a rare slow-growing tumor, and
though considered an indolent neoplasm, it does metastasiseInternational Journal of Breast Cancer 5
to lymph nodes. Surgery in the form of mastectomy with
axillary clearance is the treatment of choice.
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